Research programme: oncology therapeutics - Medac PharmaAlternative Names: MPI-2710; MPI-2720; MPI-2730; MPI-3501
Latest Information Update: 30 Jan 2014
At a glance
- Originator Medac; Medac Pharma
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Haematological malignancies
Most Recent Events
- 30 Jan 2014 Preclinical trials in Haematological malignancies in USA (unspecified route)
- 30 Jan 2014 Preclinical trials in Cancer in USA (unspecified route)